アブストラクト
Japanese
| Title | COVID-19ワクチンと甲状腺疾患 |
|---|---|
| Subtitle | [特集2] COVID-19と甲状腺疾患の現状 |
| Authors | 中泉伸彦*1, 赤水尚史*2, 宮内昭*3 |
| Authors (kana) | なかいずみのぶひこ, あかみずたかし, みやうちあきら |
| Organization | *1 : 隈病院内科, *2 : 隈病院院長, *3 : 隈病院名誉院長 |
| Journal | 日本甲状腺学会雑誌 |
| Volume | 13 |
| Number | 1 |
| Page | 52-56 |
| Year/Month | 2022 / 4 |
| Article | 報告 |
| Publisher | 日本甲状腺学会 |
| Abstract | 「要旨」新型コロナウイルス感染症 (COVID-19) の発症ならびに重症化の予防を目的とし, ワクチン接種が進んでいる. 日本においてはBNT162b2, mRNA-1273, ChAdOx1 nCoV-19/AZD1222が薬事承認され, 2022年2月16日時点で1回以上の接種者は総人口の80.2%, 2回接種完了者は79%, 3回接種完了者は11.1%と報告されている (首相官邸ホームページ : https://www.kantei.go.jp/jp/headline/kansensho/vaccine.html). しかし, ワクチン接種後に起きやすい副反応として, 比較的軽度の症状が多い一方で, アナフィラキシーといった重篤なものがまれに起こり得る. また, 報告数はきわめて少ないが, ワクチン接種後に亜急性甲状腺炎, Basedow病, 無痛性甲状腺炎を発症した症例も報告されている. その機序としてはアジュバントによるautoimmune/inflammatory syndrome induced by adjuvants (ASIA) の他, ワクチンによって産生された中和抗体が甲状腺ペルオキシダーゼ (TPO) に対して交差反応を起こし, 自己免疫性甲状腺疾患を誘発する可能性が推測されている. 現時点では, COVID-19ワクチン接種と甲状腺疾患発症の因果関係は明らかではないため, 引き続き症例の蓄積が望まれる. |
| Practice | 臨床医学：内科系 |
| Keywords | COVID-19ワクチン (COVID-19 vaccine), ASIA, 自己免疫性甲状腺疾患 (autoimmune thyroid disease), 亜急性甲状腺炎 (subacute thyroiditis), Basedow病 (Graves' disease), 無痛性甲状腺炎 (painless thyroiditis) |
English
| Title | COVID-19 vaccination and Thyroid disease |
|---|---|
| Subtitle | Feature Articles 2 |
| Authors | Nobuhiko Nakaizumi*1, Takashi Akamizu*2, Akira Miyauchi*3 |
| Authors (kana) | |
| Organization | *1 : Department of Internal Medicine, Kuma Hospital, *2 : President, Kuma Hospital, *3 : Emeritus President, Kuma Hospital |
| Journal | Journal of the Japan Thyroid Association |
| Volume | 13 |
| Number | 1 |
| Page | 52-56 |
| Year/Month | 2022 / 4 |
| Article | Report |
| Publisher | Japan Thyroid Association |
| Abstract | COVID-19 vaccinations are progressing to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Vaccines, such as BNT162b2, mRNA-1273 and AZD1222, have been approved in Japan. As of 16 February 2022, 80.2% of the total population had received at least one dose, 79% had received two doses, and 11.1% had received three doses. Although most adverse reactions to vaccines are relatively mild, serious adverse reactions, such as anaphylaxis, may occur. Moreover, a small number of cases with subacute thyroiditis, Graves' disease and painless thyroiditis have been reported after COVID-19 vaccination. It is postulated that, in addition to autoimmune/inflammatory syndrome induced by adjuvants (ASIA), neutralizing antibodies produced by vaccines, which cross-react with thyroid peroxidase (TPO) may lead to the development of autoimmune thyroiditis. At present, the causal relationship between COVID-19 vaccination and the development of autoimmune thyroiditis is not clear, and further investigations are needed. |
| Practice | Clinical internal medicine |
| Keywords | COVID-19 vaccine, ASIA, autoimmune thyroid disease, subacute thyroiditis, Graves' disease, painless thyroiditis |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) COVID19 VACCINE TRACKER. VACCINES CANDIDATES IN CLINICAL TRIALS. https://covid19.trackvaccines.org/vaccines/
- 2) Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. JAMA. 2022;327:331-40.
- 3) Pujol A, Gomez LA, Gallegos C, et al. Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-CoV2 vaccination: from Graves' disease to silent thyroiditis. J Endocrinol Invest. 2021 Nov 18; 1-8. doi:10.1007/s40618-021-01707-0. [Online ahead of print]
- 4) Iremli BG, Sendur SN, Unluturk U. Three Cases of Subacute Thyroiditis Following SARS-CoV-2 Vaccine: Postvaccination ASIA Syndrome. J Clin Endocrinol Metab. 2021;106:2600-5.
- 5) Vera-Lastra O, Ordinola Navarro A, Cruz Domiguez MP, et al. Two Cases of Graves' Disease Following SARS-CoV-2 Vaccination: An Autoimmune/Inflammatory Syndrome Induced by Adjuvants. Thyroid. 2021;31:1436-9.
残りの15件を表示する
- 6) Goblirsch TJ, Paulson AE, Tashko G, et al. Graves' disease following administration of second dose of SARS-CoV-2 vaccine. BMJ Case Rep. 2021;14:e246432.
- 7) Nakaizumi N, Fukata S, Akamizu T. Painless thyroiditis following mRNA vaccination for COVID-19. Hormones (Athens). 2022 Jan 15;1-3. doi:10.1007/s42000-021-00346-7. [Online ahead of print]
- 8) Siolos A, Gartzonika K, Tigas S. Thyroiditis following vaccination against COVID-19: Report of two cases and review of the literature. Metabol Open. 2021;12:100136.
- 9) Saygili ES, Karakilic E. Subacute thyroiditis after inactive SARS-CoV-2 vaccine. BMJ Case Rep. 2021;14:e244711.
- 10) Sahin Tekin M, Saylisoy S, Yorulmaz G. Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report. Hum Vaccin Immunother. 2021;17:4090-2.
- 11) Franquemont S, Galvez J. Subacute Thyroiditis After mRNA Vaccine for Covid-19. J Endocr Soc. 2021;5(Suppl 1):A956-7.
- 12) Capezzone M, Tosti-Balducci M, Morabito EM, et al. Silent thyroiditis following vaccination against COVID-19: report of two cases. J Endocrinol Invest. 2022 Jan 16; 1-5. doi:10.1007/s40618-021-01725-y. [Online ahead of print]
- 13) Krammer, F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516-27.
- 14) 一般社団法人日本感染症学会 ワクチン委員会・COVID-19 ワクチン・タスクフォース.COVID-19ワクチンに関する提言(第4版). https://www.kansensho.or.jp/uploads/files/guidelines/2112_covid-19_4.pdf
- 15) 東京大学医科学研究所感染・免疫部門ワクチン科学分野石井健研究室.アジュバントとは. https://vaccine-science.ims.u-tokyo.ac.jp/adjuvant/
- 16) Shoenfeld Y, Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36:4-8.
- 17) Bragazzi NL, Hejly A, Watad A, et al. ASIA syndrome and endocrine autoimmune disorders. Best Pract Res Clin Endocrinol Metab. 2020;34:101412.
- 18) Watad A, Quaresma M, Bragazzi NL, et al. The autoimmune/inflammatory syndrome induced by adjuvants (ASIA)/Shoenfeld's syndrome: descriptive analysis of 300 patients from the international ASIA syndrome registry. Clin Rheumatol. 2018;37:483-93.
- 19) Chung YH, Beiss V, Fiering SN, et al. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano. 2020;14:12522-37.
- 20) Vojdani A, Vojdani E, Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Front Immunol. 2021;11:617089.
